Preparing for a surge in COVID-19 cases this week, the Johns Hopkins health system is relying on the recently-activated Johns Hopkins Medicine Incident Command Center to prioritize the institution’s patient care and research functions and coordinate the opening of testing tents and drive-through testing sites.
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
FDA granted accelerated approval to the combination of nivolumab and ipilimumab (Opdivo and Yervoy) for patients with hepatocellular carcinoma who have been previously treated with sorafenib.
FDA has accepted Mylan's Biologics License Application or MYL-1402O, a proposed biosimilar to Avastin (bevacizumab), for review under the 351(k) pathway.
FDA has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
Thermo Fisher Scientific and Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, signed an agreement to co-develop a companion diagnostic in oncology.
The European Commission has approved Venclyxto in combination with obinutuzumab for the treatment of adult patients with chronic lymphocytic leukemia, who were previously untreated.
FDA issued a draft guidance document, “Inclusion of Older Adults in Cancer Clinical Trials Guidance for Industry,” to provide recommendations to sponsors and institutional review boards for the inclusion of older adult patients, ages 65 years and older, in the clinical trials of drugs for the treatment of cancer.
The phase III GY004 trial examining primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer failed to meet its primary endpoint of progression-free survival.
Patients who used copper intrauterine devices were found to have a lower risk of high-grade cervical neoplasms compared to users of the levonorgestrel-releasing intrauterine system, according to a Columbia study recently published in Obstetrics & Gynecology.
On March 11, Jensen, who is also William R. Jewell Distinguished Kansas Masonic Professor and professor of pathology and laboratory medicine, anatomy and cell biology, cancer biology and molecular biosciences, focused on COVID-19.
